Pembrolizumab 100mg/4ml solution for infusion vials
NHS hospitals in England used £538,348,087 of indicative cost of Pembrolizumab 100mg/4ml solution for infusion vials in the 12 months to July 2026, about 2.1% of all hospital medicines spend. That is down 7.3% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Pembrolizumab 100mg/4ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Pembrolizumab 100mg/4ml solution for infusion vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Christie Nhs Foundation Trust | £49,570,240 |
| The Royal Marsden Nhs Foundation Trust | £27,959,530 |
| Univ Hpl B/Ham Nhs Foundation Trust | £22,904,670 |
| Southend Univ Hosp Nhs Foundation Trust | £22,759,994 |
| United Lincolnshire Hospitals Nhs Trust | £19,743,410 |
| Nottingham University Hospitals Trust | £19,301,570 |
| Oxford University Hospitals Nhs Ft | £17,832,058 |
| Sheffield Teaching Hospitals Nhs Trust | £17,242,280 |
| Leeds Teaching Hpls Nhs Trust | £16,574,260 |
| University Hpls Of Leicester Nhs Trust | £14,846,350 |
The primary-care picture
Pembrolizumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Pembrolizumab medicine page.